PNC_clinical_trial.asp
 
 

JOIN US!

EXAMINATION OF AN ANTI-ALZHEIMER’S THERAPY
This research study examines the safety and effectiveness of an oral therapy called a gamma secretase inhibitor. The drug aims to block the production of Beta Amyloid—the protein believed to be critical in Alzheimer’s disease. The study involves 11 visits over 24 weeks and participants have an 80% chance of receiving active medication and a 20% chance of receiving placebo. For more information, please call (310) 794-6039.

DEPRESSION IN VASCULAR DEMENTIA
The purpose of this 8 week study is to determine how effective Zoloft (sertraline), a commonly used antidepressant medication, is in treating depression in people with vascular dementia using MRI and PET scans. For more information please contact Olivia Campa at (310) 478-3711 x42386 or olivia.campa@va.gov.

The UCLA ADC seeks volunteers to participate in our research as we explore new treatment possibilities for memory disorders, AD, and related dementias. Answers can be found only with the participation of patients and their family members. Some of these studies involve experimental medication, and some of these studies do not involve medication. Please call us if you would like more information about CLINICAL STUDIES at the UCLA ADC (310)-794-6191.

Each study has its own set of eligibility requirements. These may include

  • Diagnosis of mild to moderate AD or mild cognitive impairment (MCI)
  • Good general medical health
  • Having a study partner- a friend or relative who can accompany the study participant to the visit and answer questions about him/her.

For frequently asked questions about clinical studies

For an article about clinical trial participation by UCLA faculty